Janssen invests €150M to expand Irish biopharmaceutical facility
The expansion will take two years and add 180 new jobs.
Janssen Sciences Ireland, a subsidiary of Johnson & Johnson, is investing €150 million to expand its biopharmaceutical supply chain facility in Ringaskiddy, County Cork.
The expansion is expected to take two years and has the potential to create 180 new jobs. There will also be 300 temporary roles created during the construction phase.
Janssen has been producing medicines at the site since 2005, including those for immunology and oncology patients who have illnesses such as rheumatoid arthritis, Crohn's disease, psoriasis, psoriatic arthritis and multiple myeloma.
Today’s news follows a previous investment of €300 million in the Ringaskiddy facilities in 2017, which saw the construction of a large-scale manufacturing suite at the site. This suite will begin commercial operations shortly, after receiving all necessary manufacturing approvals.
The expansion is supported by the Irish government via the Industrial Development Agency (IDA), who say continuous investment in the facility is serving to increase operational capacity to meet the demands of a growing clinic portfolio.
Johnson & Johnson Vice President Manufacturing & Technical Operation, Leila Schwery-Bou-Diab, said the facility has been “at the cutting-edge of delivering life-changing healthcare products” since its establishment in 2005.
“The additional manufacturing capacity created by this investment will enhance the work we do to deliver transformational medicines that can change the trajectory of health,” she said.
Janssen Sciences General Manager Gary Hartnett said the continued investment in Ringaskiddy is “a real vote of confidence in the talent and dedication of our people, who I am proud to work with every single day as we strive to create a future where disease is a thing of the past.”
In 2020, the site was designated as a Global Lighthouse site by the World Economic Forum, recognising it as one of the world’s most advanced manufacturers leading the way in the adoption of Fourth Industrial Revolution technologies. The Ringaskiddy facility also operates as a Global Centre of Excellence for Clinical Drug Substance and Drug Product Release and Stability Management.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance